In April 2026, Owlet appointed founder Kurt Workman as CEO amid continued operating losses detailed in its late 2025 quarterly filing. The company’s healthcare technology business faces sustained margin compression primarily due to tariffs on products sourced from Southeast Asia. Owlet’s recurring negative cash flow and capital dependence create substantial going concern risks, even as Workman aims to steer a turnaround through cost management and growth initiatives. Industry competition and supply chain tariffs remain critical constraints, with prospects hinging on execution under new leadership.